Core Insights - Peng Ruili Group and Nanjing Ruizhong Biotechnology have signed a cooperation agreement to invest 150 million yuan in building a secondary general hospital focused on oncology in Chengdu [1][2] - The new hospital will cover over 25,000 square meters and have approximately 250 beds, aiming to provide comprehensive services for cancer prevention, diagnosis, treatment, and rehabilitation [1][2] - The project is expected to begin trial operations by the end of this year, integrating advanced cancer treatment technologies and expert resources from across the country [1][2] Investment and Development - The new hospital will focus on comprehensive cancer treatment and will explore innovative anti-cancer therapies in collaboration with Nanjing Ruizhong Biotechnology [2] - It will adopt a multidisciplinary team (MDT) approach to create personalized treatment plans for various malignant tumors, including thyroid cancer, lung cancer, liver cancer, pancreatic cancer, prostate cancer, and glioma [2] - The hospital will implement a full-cycle management model, utilizing high-precision imaging and AI-assisted diagnostic systems for early detection and treatment [2] Strategic Positioning - Chengdu Peng Ruili International Medical Health Center is the first "shared medical + high-speed rail hub" complex developed by Singapore's Peng Ruili Group in China, aiming to establish a "highland for innovative cancer treatment" [3] - The hospital will vertically integrate with other institutions within the center to enhance early cancer screening and treatment capabilities, leveraging advanced technologies such as PET-CT and AI imaging analysis [3] - The strategic location near Chengdu East Station will enable comprehensive coverage of the southwestern region, providing hope for more cancer patients through access to cutting-edge technologies [3]
成都再添一家肿瘤特色二级综合医院 国际前瞻肿瘤治疗落地成都鹏瑞利国际医疗健康中心
Sou Hu Cai Jing·2025-05-09 12:35